INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 418m ago
HOUSE PTR18m ago
SEC 13F18m ago
ROBINHOOD CHAIN18m ago
MJ
Corporate insider

Murphy Andrew J

Co-Chief Scientific OfficerCIK 0001796226

EDGAR filingsOpen in network
Disclosed transactions35
Buys / sells0 / 27
Max Insider Score22
Connections with evidence1

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Gift
G—
1,054 sh
Nov 3, 2026Nov 5, 2026
traded Nov 3, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    REGENERON PHARMACEUTICALS, INC.EVP Research · Dec 9, 2025
5
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL
$42K
55 sh
Oct 14, 2026
Oct 15, 2026
traded Oct 14, 2026
+1d
SEC FORM 4

Evidence

5
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$9,242
12 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

8
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$94K
121 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

11
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$292K
376 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

16
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M$6.49M
17.0K sh
Oct 13, 2026Oct 15, 2026
traded Oct 13, 2026
+2dSEC FORM 4

Evidence

16
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Tax withholding · 10b5-1 plan
F$9.70M
12.9K sh
Oct 13, 2026Oct 15, 2026
traded Oct 13, 2026
+2dSEC FORM 4

Evidence

5
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$4,523
6 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

5
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$18K
24 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

5
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$21K
27 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

8
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$147K
192 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

8
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$98K
127 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

8
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$163K
211 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

8
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$173K
224 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

8
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$51K
66 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

11
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$296K
380 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

11
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$361K
463 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

5
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$39K
50 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

0
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M—
17.0K sh
Oct 13, 2026Oct 15, 2026
traded Oct 13, 2026
+2dSEC FORM 4

Evidence

5
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$12K
16 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

5
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$19K
25 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

5
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$26K
35 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

5
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$30K
38 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

11
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$354K
454 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

8
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$218K
283 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

8
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$167K
219 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

8
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$207K
271 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

8
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$214K
279 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

5
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$11K
14 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

8
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$56K
74 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

8
MJ
Murphy Andrew JCo-Chief Scientific Officer
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$81K
105 sh
Oct 14, 2026Oct 15, 2026
traded Oct 14, 2026
+1dSEC FORM 4

Evidence

22
MJ
Murphy Andrew JEVP Research
REGNREGENERON PHARMACEUTICALS, INC.
Tax withholding
F$2.97M
4,229 sh
Dec 9, 2025Dec 11, 2025
traded Dec 9, 2025
+2dSEC FORM 4

Evidence

9
MJ
Murphy Andrew JEVP Research
REGNREGENERON PHARMACEUTICALS, INC.
Grant or award
A—
18.3K sh
Dec 5, 2025Dec 9, 2025
traded Dec 5, 2025
+4dSEC FORM 4

Evidence

13
MJ
Murphy Andrew JEVP Research
REGNREGENERON PHARMACEUTICALS, INC.
Grant or award
A—
3,715 sh
Dec 5, 2025Dec 9, 2025
traded Dec 5, 2025
+4dSEC FORM 4

Evidence

18
MJ
Murphy Andrew JEVP Research
REGNREGENERON PHARMACEUTICALS, INC.
Tax withholding
F$1.21M
1,699 sh
Dec 8, 2025Dec 9, 2025
traded Dec 8, 2025
+1dSEC FORM 4

Evidence